CVID & Pregnancy
Trough IgG levels and absence of acute infections, as stated above, are the best indicators of good replacement therapy in CVID patients, including pregnant women. No specific protocols for pregnant CVID patients have been published; however, doses and their intervals must be adjusted to the individual patient throughout the pregnancy.[101,102] Often, a 2-week interval may be required, mainly in the last trimester of pregnancy when, owing to the active transport of IgG to the fetus,[103,104] the largest doses are required to protect the mother and the fetus.
As pointed out previously, serologic studies in CVID patients are of no use, and the same is true for the usual serologic studies conducted in pregnant CVID women. Infections in all CVID patients, including pregnant women, should be diagnosed by identification of the infectious agent by microbiology and molecular biology techniques.
Expert Rev Clin Immunol. 2009;5(4):381-390. © 2009
Cite this: An Update on Treatment Strategies for Common Variable Immunodeficiency - Medscape - Jul 29, 2009.